/ FAYEZ NURELDINE
The Saudi Arabian Ministry of Health announced Thursday an important statement for cancer patients in the Kingdom of Drugs "Vitraki".
Vitrace, a commercial name of Larotrectinib, does not completely cure or treat cancer, and has recently circled in media and network sites, the ministry said.
He adds that the drug is trying to control cancer growth and spread as long as possible, rather than a replacement for surgical treatment, chemotherapy and radiation therapy.
Larotrectinib was included in the first and second phases, including 55 patients with TRK genetic mutation with a total response rate of 13% and a partial rate of 62%.
The study showed that the response did not last long in all patients because the disease developed in some patients and continued to respond to 39% of patients after the first year of treatment, and some patients operated after the drug.
This new treatment has recently been approved by the American Food and Drug Administration to treat specific cancer cases with a specific type of rare genetic mutation (TRK gene), and this rare breakthrough has been found in some tumors such as gallbladder cancer. In addition to treating cases that containing genetic mutation does not tolerate surgical intervention, as well as cases involving genetic mutation, and there is no suitable alternative to treatment and the cases that developed after the treatment was planned.
Source: Saudi newspaper "Riyadh"